fb-pixel tracker
News

Caris Life Sciences Enhances Molecular Profiling Service with Addition of ROS1 and MGMT-Methylation Biomarkers

New Biomarkers provide expanded therapeutic insights to improve cancer patient outcomes IRVING, Texas, Nov. 12, 2012 /PRNewswire/ – Caris Life Sciences™, a leading biosciences company focused on enabling personalized healthcare through molecular profiling and blood-based diagnostic services, has added ROS1 and MGMT-Methylation to the company’s evidence-based molecular profiling service. The company is one of only … Continued

Caris Life Sciences Selects Illumina’s MiSeq® System to Enable Next-Generation Sequencing as Part of its Molecular Profiling Service

Collaboration Enhances Breadth and Depth of Therapeutic Information to Help Oncologists Better Personalize Cancer Treatment SAN DIEGO—(BUSINESS WIRE)—November 7, 2012—Illumina, Inc. (NASDAQ:ILMN) today announced that Caris Life Sciences has selected its MiSeq sequencing system to support Caris’ evidence-based molecular profiling service. The MiSeq system will be deployed to enable rapid, simultaneous analysis of multiple genes from … Continued

Caris Life Sciences hosts preeminent personalised medicine experts at 2012 European Society for Medical Oncology (ESMO) Satellite Symposium

Industry-leading oncologists to discuss the use of molecular profiling in individualising cancer care VIENNA, AUSTRIA, Sept. 27, 2012 – Caris Life Sciences, a leading biosciences company focused on enabling personalised healthcare through molecular profiling and blood-based diagnostic services, will host a satellite symposium at the 2012 annual meeting of the European Society for Medical Oncology … Continued

Caris Life Sciences Launches Caris Target Now™ Select for NSCLC, Melanoma, and Cancers of the Breast, Colon, and Ovary

Enhanced Molecular Profiling Service Now Includes More Biomarker Analysis Options, Faster Turnaround Time, and Clinical Trial Matching Irving, Tex., June 26, 2012 — Caris Life Sciences®, a leading biosciences company focused on enabling precise and personalized healthcare through molecular profiling and blood-based diagnostic services, today announced the launch of Caris Target Now™ Select, an advanced, … Continued

Caris Target Now™ ASCO Presentations Underscore Importance of Molecular Profiling in Pancreatic Cancer and Uveal Melanoma

–Promising, Actionable Targets Identified in Both Diseases – Chicago, Ill., June 4, 2012 — Caris Life Sciences announced today that two data presentations underscore the importance of molecular profiling in patients with pancreatic cancer and uveal melanoma, with several potentially promising therapeutic targets identified in both diseases. The two datasets, both of which were assembled … Continued

Caris Life Sciences Announces Upcoming Launch of Caris Target Now Select™

Service will Offer Enhanced Biomarker Analysis for Cancers of the Breast, Colon, and Ovary, as well as NSCLC and Melanoma Irving, Tex., June 3, 2012 – Caris Life Sciences®, a leading biosciences company focused on enabling precise and personalized healthcare through molecular profiling and blood-based diagnostic services, announces the upcoming introduction of Caris Target Now … Continued

Caris Life Sciences Announces Upcoming Launch of Caris Target Now Select™

Service will Offer Enhanced Biomarker Analysis for Cancers of the Breast, Colon, and Ovary, as well as NSCLC and Melanoma Irving, Tex., June 3, 2012 – Caris Life Sciences®, a leading biosciences company focused on enabling precise and personalized healthcare through molecular profiling and blood-based diagnostic services, announces the upcoming introduction of Caris Target Now … Continued

ASCO Presentations Highlight Clinical Utility of Caris Target Now™ in Molecular Profiling of Breast and Head and Neck Cancers

  – TLE3 Biomarker Over-expressed in HER2-positive, Hormone Receptor-positive, and Triple-negative Breast Cancers –   –EGFR status May Facilitate Therapeutic Decision-making in Head and Neck Cancer – Chicago, Ill., June 2, 2012 – Caris Life Sciences, announced today the utility of the company’s Caris Target Now™ evidence-based molecular profiling service in the characterization of breast … Continued

Caris Target Now™ Data to be Showcased at ASCO 2012

Evidence-Based Molecular Profiling Service to be Featured in Eight Separate Data Presentations   IRVING, TX, May 21, 2012 – Caris Life Sciences, a leading biosciences company focused on enabling precise and personalized healthcare through molecular profiling and blood-based diagnostic services, today announced that eight data presentations on Caris Target Now™, the foremost evidence-based molecular profiling … Continued

Circulating Microvesicles Demonstrate Promise for Cancer Testing

Three Posters on Novel Technology Presented at American Association for Cancer Research (AACR) IRVING, TX, April 4th, 2012 — Caris Life Sciences, a leading biosciences company focused on enabling precise and personalized healthcare through molecular profiling and blood-based diagnostic services, this weekend presented novel findings regarding the biological role of circulating microvesicles (cMV) in the … Continued

1 18 19 20 21 22

About Our News

Search to find the latest new about Caris Molecular Intelligence®, sign up for news alerts, and be sure to follow us on social media.